Sign Up

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Elanco Animal Health Incorporated (NYSE:ELAN) reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Despite the decline, earnings exceeded both the company’s guidance range of 17 cents to 21 cents and the consensus estimate of 20 cents.

Revenue came in at $1.24 billion, surpassing the consensus estimate of $1.19 billion and exceeding management’s guidance of $1.175 billion to $1.195 billion. Sales grew 5% on a reported basis and 8% on an organic constant currency basis.

Also Read: Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

Adjusted EBITDA was $238 million in the second quarter of 2025, a 13.5% decrease.

Pet Health revenue was $643 million, an increase of 11% on a reported basis, or 10% on an organic constant currency basis.

The increase in pet health revenue included a 4% increase in price. New products primarily drove year-over-year volume increases of 6%.

The Advantage Family of products and Seresto contributed revenue of $147 million and $113 million, respectively. 

Farm Animal revenue was $583 million, a decrease of 2% on a reported basis due to the sale of the aqua business, and a ...